Thus, our results confirm the beneficial effect of FGF21, which not only protects from obesity, insulin resistance, and dyslipidemia but also prevents NAFLD, as shown in DIO mice with FGF21 deficiency in hepatocytes, where the Mat1a ASO treatment increased liver TG to higher levels than in the ASO-treated DIO control mice. The gene discussed is FGF21; the disease is Insulin resistance.